(Q45923722)

17 December 2017

title

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. (English)

1 reference

17 December 2017

1 reference

Aziz Karim

1

1 reference

17 December 2017

Aziz Laurent

2

1 reference

17 December 2017

Melvin Munsaka

3

1 reference

17 December 2017

Elisabeth Wann

4

1 reference

17 December 2017

Penny Fleck

5

1 reference

17 December 2017

Qais Mekki

6

1 reference

17 December 2017

language of work or name

1 reference

21 July 2009

1 reference

17 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

17 December 2017

volume

49

1 reference

17 December 2017

issue

10

1 reference

17 December 2017

page(s)

1210-1219

1 reference

17 December 2017

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Pioglitazone: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009338938

21 January 2018

Identifiers

DOI

10.1177/0091270009338938

1 reference

17 December 2017

1 reference

17 December 2017